

26829/88

607830

FORM 1

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

APPLICATION FOR A STANDARD PATENT

I\We, UNILEVER PLC
of UNILEVER HOUSE
BLACKFRIARS
LONDON EC4
ENGLAND

hereby apply for the grant of a standard patent for an invention entitled:

ORAL COMPOSITIONS

which is described in the accompanying complete specification

Details of basic application(s):

Number of basic application	Name of Convention country in which basic application was filed	Date of basic application
8729564	GB	18 DEC 87

My/our address for service is care of GRIFFITH HACK & CO., Patent Attorneys, 601 St. Kilda Road, Melbourne 3004, Victoria, Australia.

DATED this 13th day of December 1988

UNILEVER PLC
GRIFFITH HACK & CO.

[Handwritten signature]

TO: The Commissioner of Patents.

APPLICATION ACCEPTED AND AMENDMENTS
ALLOWED 17-12-90

Forms 7 and 8

AUSTRALIA

Patents Act 1952

DECLARATION IN SUPPORT OF A CONVENTION OR NON-CONVENTION APPLICATION FOR A PATENT OR PATENT OF ADDITION

Name(s) of Applicant(s)

In support of the application made by UNILEVER PLC

Title

for a patent for an invention entitled ORAL COMPOSITIONS

Name(s) and address(es) of person(s) making declaration

I/~~WE~~, Dilshad RAJAN
of Unilever House, Blackfriars, London EC4, England,

do solemnly and sincerely declare as follows:-

- 1. I am/~~we are~~ the applicant(s) for the patent, or ~~am/are~~ authorised by the abovementioned applicant to make this declaration on its behalf.
- 2. The basic application(s) as defined by Section 141 of the Act was/were made in the following country or countries on the following date(s) by the following applicant(s) namely:-

Country, filing date and name of Applicant(s) for the or each basic application

in Great Britain on 18th December 1987
 by Unilever PLC
 in _____ on _____ 19____
 by _____

- 3. The said basic application(s) was/were the first application(s) made in a Convention country in respect of the invention the subject of the application.

Name(s) and address(es) of the or each actual inventor

- 4. The actual inventor(s) of the said invention is/are as attached

See reverse side of this form for guidance in completing this part

- 5. The facts upon which the applicant(s) is/~~are~~ entitled to make this application are as follows:-
The Applicant would be entitled to have assigned to it a Patent granted to any of the actual Inventors in respect of the said Invention .

DECLARED at London, England this 2nd day of December 1988

Dilshad Rajan

INVENTOR(S) :

Nigel Peter BIRD
A British subject of
6 Galtres Court
Bebington
Wirral
Merseyside
L63 8RD
ENGLAND

Geoffrey Stewart INGRAM
A British subject of
The Cairngorms
4 Stanley Avenue
Bebington
Wirral
Merseyside
L63 5QF
ENGLAND

Paul Ian RILEY
A British subject of
2 Buckland Drive
Bebington
Wirral
Merseyside
L63 9AA
ENGLAND

James Alexander RITCHIE
A British subject of
11 Inley Road
Spital
Wirral
Merseyside
L63 9YS
ENGLAND

(12) PATENT ABRIDGMENT (11) Document No. AU-B-26829/88
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 607830

(54) Title
ORAL COMPOSITIONS

International Patent Classification(s)
(51)⁴ A61K 007/24 A61K 007/26

(21) Application No. : 26829/88

(22) Application Date : 13.12.88

(30) Priority Data

(31) Number (32) Date (33) Country
8729564 18.12.87 GB UNITED KINGDOM

(43) Publication Date : 22.06.89

(44) Publication Date of Accepted Application : 14.03.91

(71) Applicant(s)
UNILEVER F.L.C

(72) Inventor(s)
NIGEL PETER BIRD; GEOFFREY STEWART INGRAM; PAUL IAN RILEY; JAMES
ALEXANDER RITCHIE

(74) Attorney or Agent
GRIFFITH HACK & CO, GPO Box 1285K, MELBOURNE VIC 3001

(56) Prior Art Documents
GB 1135643

(57) Claim

1. A toothpaste having antimicrobial activity packaged within a closed container, the toothpaste containing water, an ascorbic acid compound consisting of ascorbic acid, an ascorbic acid salt or an ascorbic acid ester and a copper catalyst for the auto-oxidation of the ascorbic acid compound, said toothpaste being substantially free from lactic acid and/or a salt thereof.

607830

AUSTRALIA

PATENTS ACT 1952

Form 10

COMPLETE SPECIFICATION

(ORIGINAL)

FOR OFFICE USE

Short Title:

Int. Cl:

Application Number:
Lodged:

Complete Specification-Lodged:
Accepted:
Lapsed:
Published:

Priority:

Related Art:

This document contains the
amendments made under
Section 49 and is correct for
printing.

TO BE COMPLETED BY APPLICANT

Name of Applicant:

UNILEVER PLC

Address of Applicant: UNILEVER HOUSE
BLACKFRIARS
LONDON EC4
ENGLAND

Actual Inventor:

Address for Service: GRIFFITH HACK & CO.,
601 St. Kilda Road,
Melbourne, Victoria 3004,
Australia.

Complete Specification for the invention entitled:
ORAL COMPOSITIONS

The following statement is a full description of this invention
including the best method of performing it known to me:-

ORAL COMPOSITIONS

5 The invention relates to oral products for promoting
the health of the oral cavity. Known oral products of
this kind commonly take the form of mouthwashes and
toothpastes, also known as dental creams and which include
tooth gel compositions. A variety of active agents are
known for use in such products such as anti-caries agents,
e.g. fluoride, and anti-tartar agents, e.g.
10 pyrophosphates. Another well known group of oral health
agents are those which inhibit the growth of dental
plaque, which is composed of bacteria. The inhibition of
the growth of dental plaque and its removal from the teeth
through regular toothbrushing is important since dental
15 plaque, apart from being cosmetically undesirable, is a
precursor for a number of oral disorders. For example,
acid generated within plaque by the bacterial
decomposition of sugars can lead to dental caries, and the
mineralisation of plaque leads to the formation of tartar.
20 A number of differing agents have been proposed for use in
oral compositions for inhibiting the development of dental

plaque on the surfaces of the teeth. These agents generally have an antibacterial action. Many cationic antibacterial agents have been suggested such as the bis biguanides of which chlorhexidine is the most well known.

5 Chlorhexidine is a powerful antibacterial agent but suffers from the disadvantage of having a bitter taste and stains the teeth. Many attempts have been made to overcome these drawbacks, especially the staining problem. In US-A-3925543 (Donohue) and US-A-4213961 (Curtis et al)

10 it is suggested that inclusion of ascorbic acid is beneficial as an anti-stain agent.

It is believed that ascorbic acid was first suggested for use in a dentifrice in US-A-2 470 906 (Taylor) as a

15 means of transforming the mucinous coat in the oral cavity so that it is easily removed from, for example, tooth enamel.

It has been proposed in US-A-3 065 139 (Ericsson et

20 al) to include ascorbic acid as part of an antibacterial preparation effective against a number of bacterial species found in the oral cavity. The antibacterial preparation comprises an oxidising agent, particularly sodium percarbonate, a reducing agent being a compound

25 containing an enediol group (-COH:COH-), especially ascorbic acid, and a catalyst, such as copper, for the reduction-oxidation reaction. The patent teaches that since it is the actual oxidation process of the enediol which exert the antimicrobial action, the reacting

30 components must not be brought together in water solution until the time of application, or immediately before this application. However, they can be mixed in the form of water-free pastes such as by using water-free glycerol as a paste base.

The limited duration of the antimicrobial activity of a solution of ascorbic acid containing a catalytic amount of copper is also referred to in US-A-3 681 492 (Kotzbauer). This reference discloses that the antimicrobial life of such solutions may be lengthened by the use of nitrogeneous compounds which are capable of complexing with the copper to form a complex having a log stability constant within the range 3 to 14.

JP-B-72010399 (Sun Star) published 28 March 1972 discloses a dentifrice mainly comprising calcium secondary phosphate and also containing 0.02 to 0.20% copper chlorophyll and 0.2 to 8 times the amount of copper chlorophyll of ascorbic acid. The decomposition/colour change of copper chlorophyll and the oxidative decomposition/colouration of ascorbic acid is said to be inhibited.

GB-B-2 080 681 (Fahim & Miller) discloses a therapeutic dentifrice comprising a combination of zinc ions and ascorbic acid but there is excluded any component which would induce oxidation in ascorbic acid.

JP-A-63141921 (Kao) published 14 June 1988 discloses a dentifrice containing ascorbic acid, ascorbic acid salt or ascorbic acid ester and a water-soluble zinc salt, such as zinc chloride, zinc sulphate, zinc acetate, zinc lactate or zinc nitrate. The purpose of the zinc salt is to inhibit the formation of brown-coloured decomposition products produced on oxidation of the ascorbic acid.

We have now surprisingly found that relatively stable antimicrobial toothpaste products according to the present invention may be formulated by packing within a closed container a toothpaste composition containing water, an ascorbic acid compound consisting of ascorbic acid, an

ascorbic acid salt or an ascorbic acid ester and a copper catalyst for the auto-oxidation of the ascorbic acid compound.

5 It has furthermore been unexpectedly discovered that the toothpaste products of the present invention are effective for combating anaerobic bacteria. Therefore, the products of the invention are valuable for the control of gingivitis and/or periodontitis since anaerobic
10 bacteria are believed to be implicated in these diseases (Journal of Clinical Periodontology, 1979, 6, 351-382). In practice, of course, during use of the product some of the ascorbic acid will undergo catalysed auto-oxidation and thereby exert an anti-bacterial action against aerobic
15 bacteria.

 The ascorbic acid, also known as L ascorbic acid or Vitamin C, or salt or ester thereof, may be present in the product of the invention in an amount of from about 0.05%
20 to about 5%, preferably about 0.5% to about 5% by weight of the product. A mixture of two or more of ascorbic acid, ascorbic acid salt and ascorbic acid ester may of course be used.

25 Any physiologically acceptable salt of ascorbic acid may be used. Various alkali metal and alkaline earth metal salts are suitable. Other suitable salts are the ammonium salt and those derived from monoethanolamine, diethanolamine, and amino acids such as arginine and
30 lysine.

 Suitable ascorbic acid esters are those in which one or more hydroxy groups in the 2-, 3-, 5- and/or 6-positions are fatty acid ester, sulphate or phosphate.
35 Examples are ascorbic acid-2-acetate, ascorbic

acid-2-sulphate, ascorbic acid-2-phosphate, ascorbic acid-2-palmitate.

5 The copper catalyst is preferably incorporated in the product of the invention in the form of a water-soluble copper salt to provide the catalyst in ionic form in the aqueous liquid medium of the toothpaste. Any suitable physiologically acceptable salt may be used. Examples of suitable copper salts are copper sulphate, copper halides and pseudohalides, copper nitrate, copper salts of 10 carboxylic acids in the homologous series formic acid to decanoic acid, copper salts of polybasic acids in the series oxalic acid to suberic acid, and copper salts of hydroxycarboxylic acids including glycolic acid, lactic acid, tartaric acid, malic acid and citric acid. 15

The copper catalyst may, however, be included in the toothpaste of the invention in the form of copper ions carried or copper compounds precipitated on a solid or 20 colloidal support such as silica, a clay (e.g. montmorillonite) or upon a biopolymer or synthetic polymer. Copper compounds which are substantially insoluble but which nevertheless release sufficient copper ions to be catalytic, such as copper hydrotalcite, may 25 also be used.

It is already known from EP-A-38 867 to incorporate copper compounds in oral compositions as a source of copper ions for the purpose of producing an anti-plaque 30 effect. Various copper compounds are disclosed therein and such compounds may be incorporated in oral compositions according to this invention.

The amount of catalytic copper, calculated as the 35 metal, which may be included in compositions according to

the present invention ranges from about 1 ppm to 1000 ppm, preferably 10 to 200 ppm, more preferably 30 to 100 ppm.

5 The copper catalyst for the auto-oxidation of ascorbic acid may be used combined with other metals such as iron, manganese, nickel, cobalt and vanadium,

10 From the documents referred to above it is evident that the antibacterial activity of the copper catalysed auto-oxidation of ascorbic acid has been recognised for many years. To be active it appears that the copper must be sufficiently available for it to act as a catalyst. For example, copper which is complexed such as in copper chlorophyll as used in the compositions of JP-B-72010399
15 (Sun Star) is ineffective as a catalyst. The suitability of a copper compound as catalyst for the auto-oxidation of ascorbic acid and thus its suitability for use in compositions of this invention can readily be checked by determining whether it leads to the rapid removal of
20 dissolved oxygen from an oxygen-containing aqueous solution of ascorbic acid. Such a test, referred to herein as the Oxygen Consumption Test, may be carried out in the following way.

25 The principle of the test is that, during the copper-catalysed auto-oxidation of ascorbic acid, oxygen is consumed and the rate of loss of oxygen from a closed aqueous ascorbic acid/copper catalyst system can be easily monitored by means of an oxygen electrode. Stock
30 solutions of ascorbic acid (prepared daily at 1.0% w/w) and of the copper catalyst (100ppm Cu) were prepared by dissolving the appropriate material in distilled, oxygen-saturated water. Lower concentrations of copper catalyst were prepared by appropriate dilutions. The
35 distilled water was saturated with oxygen by leaving it overnight in a container open to the atmosphere.

The oxygen electrode was set up in oxygen-saturated distilled water in the electrode cell and the display was adjusted to show an oxygen content of 100 units. The distilled water was removed and rapidly replaced with a mixture of equal volumes of the ascorbic acid solution and the solution of the copper compound in such a way that the dilutions resulted in final concentrations of 0.5% ascorbic acid and 5ppm copper. A small magnetic follower in the base of the electrode cell ensured rapid mixing of the two solutions.

Rate of loss of oxygen from the solution can be recorded either manually by noting the digital readout of oxygen content or automatically by connecting a chart recorder to the oxygen electrode.

Water-soluble copper salts which result in a rapid consumption of oxygen exhibit catalytic activity. Such salts result in a consumption of at least 50% of the oxygen content of the water in two minutes.

The following table gives data obtained using copper sulphate and copper chlorophyllin, respectively. They show that copper chlorophyllin is not catalytically active.

	<u>Time (mins)</u>	<u>Electrode Reading (% Oxygen)</u>	
		<u>Copper salt</u>	<u>Copper chlorophyllin</u>
30	0.5	79	105
	1.0	58	101
	2.0	26	98
	4.0	5	95

35

A similar procedure can be used to show that copper in substantially insoluble form may be catalytically active. Results for basic copper carbonate precipitated onto silica (Form A) and copper hydrotalcite (Form B) are given below. In these tests 0.1g of material was combined with 8ml of 0.5% ascorbic acid solution in oxygen-saturated distilled-water.

Time (mins)	Electrode Reading (% Oxygen)	
	Cu in Form A	Cu in Form B
0.5	68	21
1.0	22	12
2.0	7	6
4.0	3	3

In one particular embodiment, the oral composition of the invention also contains an iodide or bromide, particularly an alkali metal iodide or bromide, and preferably potassium iodide. The amount of potassium iodide may be from 0.01 to 2%, such as from 0.1 to 1%, by weight of the composition. Equivalent amounts of other iodides or of bromides may be used. A mixture of an iodide and a bromide may, of course, be employed. The presence of these halides had been found to enhance the antibacterial action obtained on oxidation of the ascorbic acid compound.

In another embodiment of the invention the toothpaste product also includes a source of zinc ions to provide an enhanced therapeutic effect.

The beneficial action of zinc salts is already known. A large number of zinc salts suitable for use in oral compositions are disclosed in US-A-4 100 269, US-A-4 022 880 4 160 821 and US-A-4 656 031. These include by way of

example, zinc citrate, zinc chloride and zinc sulphate. Examples of other zinc salts that have been proposed are zinc carboxymethyloxysuccinate (US-A-4 144 323), zinc glycinate (US-A-4 339 432), and zinc aspartate (US-A-4 622 220).

The amount of the zinc salt used in the oral composition of the invention may be from about 0.05% to about 1.5%, preferably from about 0.1% to about 0.7%, calculated as zinc.

The oral composition of the invention is in the form of a toothpaste, by which term we include products sometimes referred to as dental creams or gels.

Toothpaste usually comprise a suspension of a particulate solid abrasive cleaning agent in a thickened aqueous humectant liquid.

In the oral composition of this invention various of the known abrasive cleaning agents can be used but silica abrasives are preferred. A number of forms of silica are already known in the art as being suitable for dentifrice use including silica xerogels, precipitated silicas and crystalline silicas. Such silicas are referred to in US-A-3 538 230 and GB-A-2 167 856. Other compatible abrasives include water-insoluble sodium metaphosphate, alumina, calcium pyrophosphate and plastics materials. Alumina abrasives include the hydrated aluminas. A conventional level of abrasive ranging from 5 to 75% by weight of the toothpaste may be used. As is well know, use of various silica abrasives permits the toothpaste to be formulated in the form of a transparent or translucent gel product.

Humectants which may be used include glycerol, sorbitol syrup, polyethylene glycol, lactitol, xylitol or

hydrogenated corn syrup. The total amount of humectant present will generally range from 10% to 85% by weight of the toothpaste, more usually 20% to 60%.

5 The remaining liquid phase of toothpaste according to the invention mainly comprises water which will usually amount to from about 5% to about 45% by weight of the toothpaste. The amount of water in the toothpaste, including any present in the humectant, will generally be
10 in the range about 5% to about 60%, such as from about 10% to about 55% by weight of the toothpaste.

Numerous binding or thickening agents have been indicated for use in toothpastes, preferred ones being
15 hydroxymethylcellulose, sodium carboxymethylcellulose and xanthan gum. Others include natural gum binders such as gum tragacanth, gum karaya and gum arabic, Irish moss alginates and carrageenans. Silica thickening agents include the silica aerogels and various precipitated
20 silicas. Mixtures of binders and thickening agents may be used. The amount of binder and thickening agent included in a toothpaste is generally between 0.1 to 10% by weight.

Toothpastes generally also comprise a surfactant .
25 Commonly used is sodium lauryl sulphate but others are also known to be suitable. The amount of surfactant is usually within the range 0.5 to 5% by weight of the composition.

30 A variety of other known toothpaste ingredients may also be included in toothpastes formulated in accordance with the present invention. Such ingredients include an anti-carries ingredient such as sodium fluoride or sodium monofluorophosphate or other effective fluorine-containing
35 compound; an additional anti-plaque agent such as an antimicrobial compound for example chlorhexidine or 2,4,

4'-trichloro-2'-hydroxy-diphenyl ether; sweetening agent such as saccharin; an opacifying agent such as titanium dioxide; a preservative such as formalin; a flavouring agent such as peppermint oil or spearmint oil; a colouring agent; or pH controlling agent such as an acid, base or buffer, for example benzoic acid, to give a pH of from about 4 to about 8, preferably about 5 to about 7. In order to minimise any slight surface discolouration of an extruded toothpaste ribbon lower pHs are preferable such as about 4 to about 5.

Preferred oral compositions of this invention contain 500-5000 ppm F, preferably 1000-2500 ppm F, as ionic fluoride or monofluorophosphate.

For a further discussion of the formulation of toothpastes reference is made to Harry's Cosmeticology, Seventh Edition 1982, Edited by J B Wilkinson and R J Moore, pages 609 to 617.

The toothpaste of the invention is packed with a suitable closed container using conventional procedures. Such containers include a toothpaste tube, commonly constructed of aluminium or a laminated plastic material, a pump dispenser or an aerosol can.

As is apparent from the documents referred to above the antibacterial activity of the copper catalysed auto-oxidation of ascorbic acid has been recognised for many years. Previous studies have concluded that bacterial inhibition was due to hydrogen peroxide formed during the auto-oxidation of ascorbic acid (see J.Bacteriol. 68, 622-626, 1954).

In the study reported below combinations of copper and ascorbic acid have been tested under strict anaerobic

conditions. Under these conditions no oxygen would be present to enable auto-oxidation of the ascorbic acid reaction sequence to reach completion and no hydrogen peroxide would be formed.

5

Areas of anaerobiosis are encountered in both supra and sub-gingival plaque from where large numbers of obligate anaerobic bacteria can be isolated. Microbiological and immunological evidence has implicated anaerobic bacteria in the etiology of periodontal diseases.

10

Test Procedure

15

1. A medium based on that developed by Socransky et al (J.Clin.Microbiol, 22, 2, 303-305) was used because of its low residual copper content. L-ascorbic acid was added to give a final concentration of 0.3 and 0.5% and the pH was adjusted to 6.8 using 1N sodium hydroxide. The medium was dispensed into 4.8ml volumes and was reduced by placing in an anaerobic environment.

20

25

2. Bacterial cell suspensions were prepared from colonies growing anaerobically on supplemented blood agar (see Anaerobe Laboratory Manual 4th Edition, p144, 1977, by Holdeman et al) emulsified in a small volume of distilled water. Final cell density was adjusted to approximately 1.0 at 570nm.

30

35

3. 100µl cell suspension was used to inoculate the medium containing ascorbic acid and then 30-100µl of a stock solution of copper sulphate ($\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$) was added to give final concentrations of 15, 30 and 50µg/ml copper. The test systems were mixed by

inversion and then incubated until growth was recorded in corresponding control broths.

- 4. Minimum inhibitory concentration was determined as the lowest concentration of copper/ascorbic acid which prevented visible growth.
- 5. An aliquot from broths was plated onto supplemented blood agar to confirm that cells were dead. Plates were incubated until growth was obtained on corresponding controls.

Steps 2-5 were all performed in an anaerobic cabinet under an environment of 10% hydrogen, 10% carbon dioxide and 80% nitrogen. Medium, test solutions and equipment were sterilised by autoclaving. The results are given in the following table.

Strain Reference	% Ascorbic Acid:	0.3			0.5		
		µg/ml copper:					
		15	30	50	15	30	50
20	Streptococcus sanguis 200	+	+	-	+	+	-
	" " 201	+	+	+	+	+	-
	" " 204	+	+	-	+	+	-
25	" " 205	+	+	-	+	-	-
	Streptococcus mutans M1	+	+	-	+	+	-
	Actinomyces naeslundii A3	+	+	-	+	-	-
	" " 422	+	+	-	+	-	-
	Actinomyces viscosus A1	+	+	-	+	-	-
30	Bacteroides melaninogenicus 1	+	-	-	+	-	-

+ = turbid growth
- = no obvious growth

3.5 A corresponding control containing no copper and no ascorbic acid showed growth. In the presence of 0.3%

ascorbic acid some but not all the strains were inhibited by 50µg/ml copper. In 0.5% ascorbic acid half strains were inhibited by 30µg/ml copper and all strains tested were inhibited by 50µg/ml copper. One broth showing no obvious growth of each strain was tested to confirm cell death, in all cases no viable cells were recovered. The growth of the obligate anaerobe Bacteroides melaninogenicus confirmed that anaerobic conditions were maintained during the test.

In tests utilising the same growth medium but carried out under aerobic conditions similar results were obtained. In these further tests it was determined that the minimum inhibitory concentration for copper alone was above 100 ppm and between 100 and 150 ppm, and for ascorbic acid alone the minimum inhibitory concentration was above 1%, being between 1% and 2%.

The present invention therefore in a further aspect relates to the use of compositions comprising effective amounts of copper and ascorbic acid for inhibiting the growth of anaerobic bacteria in the oral cavity, and to the use of copper and ascorbic acid for the manufacture of stable toothpaste oral compositions for combating anaerobic bacteria in the oral cavity.

The following examples illustrate the invention. Percentages are by weight.

Example 1

A toothpaste was made having the following composition.

5

<u>Ingredient</u>	<u>%</u>
Abrasive silica	10.00
Thickening silica	8.00
10 Sorbitol syrup (70% solution)	40.50
Xanthan gum	1.00
Sodium lauryl sulphate	1.50
Sodium monofluorophosphate	0.82
Titanium dioxide	1.00
15 Ascorbic acid	2.00
Copper sulphate pentahydrate	0.019*
Saccharin	0.20
Flavour	1.00
Water	to 100.00

20

* corresponds to about 50ppm Cu

25

30

35

The toothpaste is made using conventional procedures and conventional toothpaste mixers. The copper sulphate is added early in the process with other water-soluble ingredients such as saccharin and sodium monofluorophosphate. The ascorbic acid is added as a solution in water, adjusted to pH 5 with sodium hydroxide, after the detergent and prior to the flavour in the final stages of the process. As in conventional processes, all mixing is carried out under vacuum. Finally the toothpaste is filled into plastic laminate tubes using standard filling equipment within 24 hours of manufacture and the tubes closed by heat sealing in the usual way.

In an in vitro plaque test the above toothpaste was shown to inhibit the formation of dental plaque. The test was performed on the toothpaste just after it had been prepared and also two weeks later when a similar level of plaque inhibition was obtained indicating that the paste had not lost activity over time. This result is consistent with the finding that the ascorbic acid in the above toothpaste is stable in spite of the presence of copper. Analysis for ascorbic acid after 4 months storage at ambient temperature gave a value of 1.9% by iodine titration whereas the nominal level was 2.0%.

Even after 5 months storage of the toothpaste the copper was still active to catalyse the auto-oxidation of the ascorbic acid. This was shown by using a slurry of the toothpaste in the oxygen consumption test described above. In this case one part by weight of the toothpaste was slurried with 6 parts by weight of oxygen-saturated distilled water. A comparative experiment was also carried out using a placebo paste containing no ascorbic acid and no copper. The results were as follows.

<u>Time (mins)</u>	<u>Electrode Reading (% Oxygen)</u>	
	<u>Toothpaste of Invention Aged 5 months</u>	<u>Placebo</u>
1.0	66	90
2.0	42	80
30 4.0	9	-
10.0	3	71

Example 2

A toothpaste was made having the following composition.

5

<u>Ingredient</u>	<u>%</u>
Silica xerogel	10.0
Silica aerogel	8.0
10 Sorbitol syrup (70% solution)	40.0
Xanthan gum	1.0
Sodium lauryl sulphate	1.5
Zinc citrate trihydrate	0.5
Ascorbic acid	2.0
15 Copper sulphate pentahydrate	0.0038*
Potassium iodide	1.0
Sodium monofluorophosphate	1.12
Sodium saccharin	0.2
Titanium dioxide	1.0
20 Flavour	1.0
Water	to 100.00

* correspond to about 10 ppm Cu.

25

The toothpaste was manufactured and filled into a container and the container then closed in the manner described in Example 1.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A toothpaste having antimicrobial activity packaged within a closed container, the toothpaste containing water, an ascorbic acid compound consisting of ascorbic acid, an ascorbic acid salt or an ascorbic acid ester and a copper catalyst for the auto-oxidation of the ascorbic acid compound, said toothpaste being substantially free from lactic acid and/or a salt thereof.
2. A toothpaste as claimed in claim 1 wherein the copper catalyst is present in the toothpaste in the form of a water-soluble copper salt.
3. A toothpaste as claimed in claim 1 or claim 2 wherein the amount of copper is 1 to 1000 ppm by weight of the toothpaste.
4. A toothpaste as claimed in claim 3 wherein the amount of copper is 10 to 200 ppm.
5. A toothpaste as claimed in claim 4 wherein the amount of copper is 30 to 100 ppm.
6. A toothpaste as claimed in any of the preceding claims wherein the ascorbic acid compound is present in an amount of from 0.05% to 5% by weight of the toothpaste.
7. A toothpaste as claimed in claim 6 wherein the amount of the ascorbic acid compound is present in an amount of from 0.5% to 5% by weight of the toothpaste.
8. A toothpaste as claimed in any of the preceding claims wherein the amount of water is from 5% to 60% by weight of the toothpaste.



9. A toothpaste as claimed in any of the preceding claims wherein the toothpaste also comprises a water soluble alkali metal iodide or bromide.
10. A toothpaste as claimed in any of the preceding claims wherein the toothpaste also comprises a source of zinc ions.
11. A toothpaste as claimed in any of the preceding claims packaged in a tube, pump or aerosol dispenser.
12. The combination of a copper salt and ascorbic acid or salt or ester thereof, when used for inhibiting the growth of anaerobic bacteria in the oral cavity.

DATED THIS 7TH DAY OF DECEMBER 1990

UNILEVER PLC

By its Patent Attorneys:

GRIFFITH HACK & CO.

Fellows Institute of Patent
Attorneys of Australia.

